S
Sherri L. Brown
Researcher at Stanford University
Publications - 12
Citations - 1459
Sherri L. Brown is an academic researcher from Stanford University. The author has contributed to research in topics: Antibody & Lymphoma. The author has an hindex of 10, co-authored 12 publications receiving 1447 citations. Previous affiliations of Sherri L. Brown include University of Washington.
Papers
More filters
Journal ArticleDOI
Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
Oliver W. Press,Janet F. Eary,Christopher C. Badger,Paul J. Martin,F R Appelbaum,Ronald Levy,Robert C. Miller,Sherri L. Brown,Wil B. Nelp,Kenneth A. Krohn +9 more
TL;DR: The tolerable toxicity and encouraging efficacy warrant further dose escalation in this phase I trial of anti-CD37 monoclonal antibody MB-1, and all five patients showed preferential localization and retention of MoAb at tumor sites.
Journal ArticleDOI
Granulocyte colony-stimulating factor mobilized peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy
Nelson J. Chao,Jeffrey Schriber,Kevin Grimes,Gwynn D. Long,Robert S. Negrin,Cathleen M. Raimondi,Sandra J. Horning,Sherri L. Brown,Langdon L. Miller,Karl G. Blume +9 more
TL;DR: Hematopoietic growth factors used to accelerate engraftment after bone marrow transplantation and to "mobilize" peripheral blood progenitor cells (PBPC) resulted in a significantly accelerated time to recovery of granulocytes and a statistically significant difference in total costs.
Journal ArticleDOI
Myelodysplasia syndrome and acute myeloid leukemia in patients with congenital neutropenia receiving G-CSF therapy.
Melvin H. Freedman,Mary Ann Bonilla,Carol Fier,Audrey Anna Bolyard,Debra Scarlata,Laurence A. Boxer,Sherri L. Brown,Bonnie Cham,George Kannourakis,Sally E. Kinsey,Pier Georgio Mori,Tammy Cottle,Karl Welte,David C. Dale +13 more
TL;DR: Improved survival of congenital neutropenia patients receiving G-CSF therapy may allow time for the expression of the leukemic predisposition that characterizes the natural history of these disorders.
Journal ArticleDOI
Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha interferon.
Sherri L. Brown,Richard A. Miller,Sandra J. Horning,Debra K. Czerwinski,Sarah Hart,Roxena McElderry,Teresa Y. Basham,Roger A. Warnke,Thomas C. Merigan,Ronald Levy +9 more
TL;DR: An update of the original trial of anti-idiotype antibodies alone and a clinical trial combining these two agents are provided to improve the initial rate of response to this treatment.
Journal Article
Imaging and treatment of B-cell lymphoma
Janet F. Eary,Oliver W. Press,Christopher C. Badger,Lawrence D. Durack,Karen Y. Richter,Stanley J. Addison,Kenneth A. Krohn,Darrell R. Fisher,Bruce A. Porter,David L. Williams,Paul J. Martin,Frederick R. Appelbaum,Ronald Levy,Sherri L. Brown,Richard A. Miller,Wil B. Nelp,Irwin D. Bernstein +16 more
TL;DR: The methods and results of quantitative imaging, biodistribution data collection, and absorbed radiation dose estimation in patients with lymphoma receiving high level radioimmunotherapy with 131I-labeled antibodies are detailed.